Add to ORKGAIM: To assess CA-125 in defining tumor response in patients treated with paclitaxel. RESULS: CA-125 criteria gave response rates very similar to the standard response rates, both for patients treated with platinum (75% vs 63%) and also for those treated with paclitaxel (40% vs 39%). Rates of false-positive prediction of response by CA-125 were also similar for patients treated with these two agents
Seven CA 125 immunoassays were compared for their clinical performance. CA 125 concentrations were d...
Background: The aim of this study was to assess the prognostic value of cancer antigen (CA) 125 and ...
Background: Ovarian cancer is the most common gynaecological malignancy. Neo adjuvant chemotherapy (...
AIM: To assess CA-125 in defining tumor response in patients treated with paclitaxel. RESULS: CA-125...
Data on CA-125 as a predictor of disease progression (PD) in ovarian cancer come predominantly from ...
BACKGROUND: CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remain...
Background: The tumor marker Cancer Antigen 125 (CA 125), though not ovarian cancer specific, is wid...
Various kinetic parameters of serum CA-125 have been reported to have better correlation with outcom...
OBJECTIVES: Serum CA 125 kinetics during early chemotherapy has a strong predictive and prognosti...
Various kinetic parameters of serum CA-125 have been reported to have better correlation with outcom...
Background: Limited evidence exists to support CA-125 as a valid surrogate biomarker for progression...
The role of the tumor markers CA125 and CA72-4 has been evaluated in the diagnosis and management of...
Objective: Defining the reliability of cancer antigen-125-related kinetics criteria versus Gynecolog...
This preliminary study included 25 patients with primary epithelial ovarian cancer (EOC) (18 serous,...
Objective. The relationship between survival and early changes in the serum level of the CA-125 anti...
Seven CA 125 immunoassays were compared for their clinical performance. CA 125 concentrations were d...
Background: The aim of this study was to assess the prognostic value of cancer antigen (CA) 125 and ...
Background: Ovarian cancer is the most common gynaecological malignancy. Neo adjuvant chemotherapy (...
AIM: To assess CA-125 in defining tumor response in patients treated with paclitaxel. RESULS: CA-125...
Data on CA-125 as a predictor of disease progression (PD) in ovarian cancer come predominantly from ...
BACKGROUND: CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remain...
Background: The tumor marker Cancer Antigen 125 (CA 125), though not ovarian cancer specific, is wid...
Various kinetic parameters of serum CA-125 have been reported to have better correlation with outcom...
OBJECTIVES: Serum CA 125 kinetics during early chemotherapy has a strong predictive and prognosti...
Various kinetic parameters of serum CA-125 have been reported to have better correlation with outcom...
Background: Limited evidence exists to support CA-125 as a valid surrogate biomarker for progression...
The role of the tumor markers CA125 and CA72-4 has been evaluated in the diagnosis and management of...
Objective: Defining the reliability of cancer antigen-125-related kinetics criteria versus Gynecolog...
This preliminary study included 25 patients with primary epithelial ovarian cancer (EOC) (18 serous,...
Objective. The relationship between survival and early changes in the serum level of the CA-125 anti...
Seven CA 125 immunoassays were compared for their clinical performance. CA 125 concentrations were d...
Background: The aim of this study was to assess the prognostic value of cancer antigen (CA) 125 and ...
Background: Ovarian cancer is the most common gynaecological malignancy. Neo adjuvant chemotherapy (...